Two Doses of Dexmedetomidine as Adjuvent to Bupivacaine in Tap Block
Status:
NOT_YET_RECRUITING
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
The aim of this study to determine the optimal dose of dexmedetomidine as an adjuvant to bupivacaine in U.S guided TAP block for preemptive analgesia In patients undergoing lower abdominal cancer surgeries.